BioCentury | Sep 30, 2011
Company News

Millennium partners with myeloma foundation

Millennium Pharmaceuticals Inc. partnered with the Multiple Myeloma Research Foundation, becoming the first company to support the foundation's Personalized Medicine Initiative program. Millennium will provide undisclosed funding to the eight-year initiative, which is conducting the...
BioCentury | Jul 7, 2003
Finance

Ebb & Flow

Last August, what looked like positive Phase III data for its Actimmune interferon gamma-1b to treat idiopathic pulmonary fibrosis helped InterMune (ITMN) to a four-month 42% run-up through the end of 2002. But the first...
BioCentury | May 26, 2003
Finance

Momentum

...a big buyer of the sector. The RiverView Group, the private equity fund affiliated with Millennium Partners...
BioCentury | Nov 13, 2000
Finance

Schroder's plans for IBT

...from sales of minor positions in non-core investments, such as Amgen (AMGN) and Biogen (BGEN). Millennium Partners...
BioCentury | Nov 8, 2000
Financial News

Schroder Ventures to manage IBT

...and Rothschild never were completed, as Rothschild decided to keep the fund. Earlier this year, Millennium Partners...
BioCentury | Jul 10, 2000
Finance

Stocks on the barbie

...sign off the outcome for undisclosed technical reasons. The meeting was held in response to Millennium Partners'...
BioCentury | Jul 10, 2000
Financial News

IBT to increase cash-out

...at last Friday's extraordinary general meeting, held at the demand of IBT's 10.06 percent shareholder, Millennium Partners...
BioCentury | Jul 7, 2000
Top Story

IBT plays up to shareholders

...The management of International Biotechnology Trust (LSE:IBT) is steadily caving in to the requests of Millennium Partners...
BioCentury | Jul 3, 2000
Top Story

IBT: Liquidation not in the cards

...a letter to shareholders, the International Biotechnology Trust (LSE:IBT) investment fund has rebuffed calls by Millennium Partners...
BioCentury | Jun 29, 2000
Top Story

Rothschild back in biotech

...biotechnology companies in which to invest," RAM said. The decision comes at a time when Millennium Partners...
Items per page:
1 - 10 of 15
BioCentury | Sep 30, 2011
Company News

Millennium partners with myeloma foundation

Millennium Pharmaceuticals Inc. partnered with the Multiple Myeloma Research Foundation, becoming the first company to support the foundation's Personalized Medicine Initiative program. Millennium will provide undisclosed funding to the eight-year initiative, which is conducting the...
BioCentury | Jul 7, 2003
Finance

Ebb & Flow

Last August, what looked like positive Phase III data for its Actimmune interferon gamma-1b to treat idiopathic pulmonary fibrosis helped InterMune (ITMN) to a four-month 42% run-up through the end of 2002. But the first...
BioCentury | May 26, 2003
Finance

Momentum

...a big buyer of the sector. The RiverView Group, the private equity fund affiliated with Millennium Partners...
BioCentury | Nov 13, 2000
Finance

Schroder's plans for IBT

...from sales of minor positions in non-core investments, such as Amgen (AMGN) and Biogen (BGEN). Millennium Partners...
BioCentury | Nov 8, 2000
Financial News

Schroder Ventures to manage IBT

...and Rothschild never were completed, as Rothschild decided to keep the fund. Earlier this year, Millennium Partners...
BioCentury | Jul 10, 2000
Finance

Stocks on the barbie

...sign off the outcome for undisclosed technical reasons. The meeting was held in response to Millennium Partners'...
BioCentury | Jul 10, 2000
Financial News

IBT to increase cash-out

...at last Friday's extraordinary general meeting, held at the demand of IBT's 10.06 percent shareholder, Millennium Partners...
BioCentury | Jul 7, 2000
Top Story

IBT plays up to shareholders

...The management of International Biotechnology Trust (LSE:IBT) is steadily caving in to the requests of Millennium Partners...
BioCentury | Jul 3, 2000
Top Story

IBT: Liquidation not in the cards

...a letter to shareholders, the International Biotechnology Trust (LSE:IBT) investment fund has rebuffed calls by Millennium Partners...
BioCentury | Jun 29, 2000
Top Story

Rothschild back in biotech

...biotechnology companies in which to invest," RAM said. The decision comes at a time when Millennium Partners...
Items per page:
1 - 10 of 15